Gadolinium-based contrast agents used in MRI scans have been linked to a number of adverse side effects, most notably nephrogenic systemic fibrosis and nephrogenic fibrosing dermopathy.

Nephrogenic systemic fibrosis and nephrogenic fibrosing dermopathy are actually the same condition. When first described in medical literature in 2000, researchers and physicians gave the condition the name “nephrogenic fibrosing dermopathy” because initial observations noted the fibrosing effect only on the skin. The name was changed when evidence showed the malady also affected internal organs, muscles, and tendons. Nephrogenic systemic fibrosis reflects that new understanding of the disease’s effect on the entire system.

Nephrogenic systemic fibrosis has been linked to gadolinium-based contrast agents. The condition appears to only occur in patients with some form of kidney disease. The term “nephrogenic” means beginning with the kidney. Researchers have theorized that the increasing number of cases of NSF has to do with increased use of gadolinium-based contrast agents in renal disease patients. Experts now recommend tests that screen for kidney disease in those about to undergo MRI.

If you have developed NSF after being exposed to a gadolinium-based contrast agent, please contact the NSF Attorneys of Williams Kherkher by calling 800-761-3187.